. Author manuscript; available in PMC: 2008 Mar 17.

Published in final edited form as: J Clin Endocrinol Metab. 2007 Jan 9;92(4):1502–1509. doi: 10.1210/jc.2006-2275

Table 1.

Demographic characteristics and baseline quantitative traits according to genotype at PPARG P12A in the Diabetes Prevention Program

	Genotype
Baseline trait	P/P (n=2,942)	A/X (n=605)	P^*
Treatment
Placebo	831 (83.1)	169 (16.9)	0.14
Metformin	831 (84.0)	158 (16.0)
Lifestyle	839 (83.6)	165 (16.4)
Troglitazone	441 (79.6)	113 (20.4)

Male	957 (81.7)	214 (18.3)	0.18
Age in years	50.8 ± 10.5	50.9 ± 10.9	0.83
Body mass index (kg/m²)	34.0 ± 6.7	34.2 ± 6.4	0.41
Waist (cm)	105 ± 14.5	107 ± 14.5	0.002

Glycemic trait
Ins Index [(μU/ml)/(mg/dl)]	1.24 ± 0.93	1.23 ± 0.90	0.73
ISI [(μU/ml)x(mmol/L)]⁻¹	0.194 ± 0.130	0.194 ± 0.126	0.93
Fasting glucose (mg/dl)	106.9 ± 8.2	106.7 ± 8.1	0.60
2-hour glucose (mg/dl)	164.8 ± 17.0	164.5 ± 17.3	0.66

Plus-minus values are means ± SD, other values are n (%).

Based on t-tests for continuous variables and chi-square for categorical variables; traits were log transformed for statistical analyses where appropriate. Ins Index, insulinogenic index; ISI, insulin sensitivity index. One sample failed genotyping.